Incyte Corp. Daily Stock Analysis

Daily Stock Analysis, INCY, Incyte Corp, priceseries

Incyte Corp. Daily Stock Analysis
Stock Information
Open
69.93
Close
70.62
High
71.40
Low
69.73
Previous Close
70.05
Daily Price Gain
0.57
YTD High
76.50
YTD High Date
Jan 21, 2022
YTD Low
65.60
YTD Low Date
Feb 14, 2022
YTD Price Change
-3.35
YTD Gain
-4.53%
52 Week High
88.26
52 Week High Date
Jun 28, 2021
52 Week Low
61.91
52 Week Low Date
Nov 2, 2021
52 Week Price Change
-7.22
52 Week Gain
-9.28%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 5. 2017
104.81
Jan 30. 2017
118.45
16 Trading Days
13.02%
Link
LONG
Mar 8. 2017
136.00
Mar 21. 2017
143.27
9 Trading Days
5.35%
Link
LONG
May 17. 2017
120.49
May 30. 2017
129.87
8 Trading Days
7.79%
Link
LONG
Jun 19. 2017
122.28
Jun 29. 2017
130.30
8 Trading Days
6.56%
Link
LONG
May 9. 2018
64.35
Jun 25. 2018
72.29
32 Trading Days
12.34%
Link
LONG
Aug 14. 2018
66.45
Sep 6. 2018
71.45
16 Trading Days
7.52%
Link
LONG
Jan 3. 2019
68.06
Jan 23. 2019
74.49
13 Trading Days
9.45%
Link
LONG
Oct 28. 2019
79.86
Dec 12. 2019
93.23
32 Trading Days
16.75%
Link
LONG
Mar 30. 2020
72.17
Apr 28. 2020
97.17
20 Trading Days
34.64%
Link
LONG
Jun 16. 2020
95.53
Jun 26. 2020
102.29
8 Trading Days
7.08%
Link
LONG
Dec 13. 2021
67.81
Jan 4. 2022
72.07
15 Trading Days
6.29%
Link
Company Information
Stock Symbol
INCY
Exchange
NasdaqGS
Company URL
http://www.incyte.com
Company Phone
3024986700
CEO
Hervé Hoppenot
Headquarters
Delaware
Business Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE 19803
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000879169
About

Incyte Corp. is a biopharmaceutical company, which focuses on the discovery, development, development, formulation, manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. Its product, Jakafi, a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. The companywas founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Description

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The company's clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the company's clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading